Biolight Life Sciences Ltd
TASE:BOLT
Intrinsic Value
BioLight Life Sciences Ltd. engages in the management, research and development, investments or sale of solutions, the purpose of which is to address a real need that exists in the field of eye diseas... [ Read More ]
The intrinsic value of one BOLT stock under the Base Case scenario is 20.89 ILS. Compared to the current market price of 350 ILS, Biolight Life Sciences Ltd is Overvalued by 94%.
Valuation Backtest
Biolight Life Sciences Ltd
Run backtest to discover the historical profit from buying and selling BOLT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Biolight Life Sciences Ltd
| Current Assets | 9.1m |
| Cash & Short-Term Investments | 8.6m |
| Receivables | 414k |
| Non-Current Assets | 24.4m |
| Long-Term Investments | 19.4m |
| PP&E | 4.3m |
| Intangibles | 686k |
| Other Non-Current Assets | 69k |
| Current Liabilities | 2.3m |
| Accounts Payable | 2.2m |
| Other Current Liabilities | 91k |
| Non-Current Liabilities | 1.4m |
| Other Non-Current Liabilities | 1.4m |
Earnings Waterfall
Biolight Life Sciences Ltd
|
Revenue
|
118k
ILS
|
|
Operating Expenses
|
-10.8m
ILS
|
|
Operating Income
|
-10.7m
ILS
|
|
Other Expenses
|
-15.4m
ILS
|
|
Net Income
|
-26m
ILS
|
Free Cash Flow Analysis
Biolight Life Sciences Ltd
BOLT Profitability Score
Profitability Due Diligence
Biolight Life Sciences Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Biolight Life Sciences Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
BOLT Solvency Score
Solvency Due Diligence
Biolight Life Sciences Ltd's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
Biolight Life Sciences Ltd's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BOLT Price Targets Summary
Biolight Life Sciences Ltd
Shareholder Return
BOLT Price
Biolight Life Sciences Ltd
| Average Annual Return | -8.81% |
| Standard Deviation of Annual Returns | 45.91% |
| Max Drawdown | -76% |
| Market Capitalization | 15.3m ILS |
| Shares Outstanding | 43 832 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
BioLight Life Sciences Ltd. engages in the management, research and development, investments or sale of solutions, the purpose of which is to address a real need that exists in the field of eye diseases. Its portfolio companies are IOptima Novel Glaucoma Treatment and Micromedic Technologies Ltd. The firm provides each of the subsidiaries with ongoing support, resources and expertise in science, regulation, business development, and intellectual property. IOptima Novel Glaucoma Treatment is engaged in the development, manufacturing and distribution of novel surgical treatments for glaucoma. Micromedic Technologies Ltd focuses, through its investee companies, on the development and commercialization of novel molecular biomarkers related to cancer, including early detection of disease, genetic risk and optimization of treatment modalities.
Contact
IPO
Employees
Officers
The intrinsic value of one BOLT stock under the Base Case scenario is 20.89 ILS.
Compared to the current market price of 350 ILS, Biolight Life Sciences Ltd is Overvalued by 94%.
You don't have any saved screeners yet
